Aim: Recent studies with extended release (ER) niacin in patients receiving intensive statin treatment with very low levels of low-density lipoprotein cholesterol (LDL-C) showed no benefit. In HPS2-THRIVE there was a trend for better outcomes in subgroups with higher baseline LDL-C or apolipoprotein (apo) B. We compared the lipid responses to ER niacin/ laropiprant in Chinese patients with and without familial hypercholesterolaemia (FH) to identify if those with higher baseline LDL-C might benefit.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2015 Published by Elsevier Inc.